NCT04211597View on ClinicalTrials.gov

EGF-loaded Chitosan to Facilitate Healing and Prevent Scar Formation of Cesarean Wound

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

April 20, 2018

Study Completion Date

December 28, 2018

Conditions
Cesarean WoundScar; Previous Cesarean Section, Complicating Pregnancy or Childbirth, Affecting Fetus or Newborn
Interventions
OTHER

Control

No scar prevention or treatment.

OTHER

Silicone gel

Dermatix® (Dermatix® Ultra, Menarini Asia-Pacific, Taiwan FDA approved)

OTHER

microencapsulated polysaccharide and oligopeptide-1(Me-EGF) 40 mcg & 5 mcg

4ml (40 mcg) of Me-EGF spray will be given by the operating physician prior to wound closure, followed by daily application of 5 mcg until day +5 after delivery. Starting from day +14, participants will receive FDA approved Silicone gel to be applied to the Cesarean wound twice a day for two months. Participants also receive routine post-partum care as usual.

Trial Locations (1)

204

Keelung Chang Gung Memorial Hospital, Keelung

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT04211597 - EGF-loaded Chitosan to Facilitate Healing and Prevent Scar Formation of Cesarean Wound | Biotech Hunter | Biotech Hunter